A review of life science current events reported by MedCity News this week: Grifols and Talecris get FTC approval to merge. The FTC had been concerned that a merger of two of the top companies in the specialized blood therapeutics space would hurt competition and lead to higher drug costs for patients. Cleveland Clinic CEO: […]
Grifols‘ (MCE:GRF) $4 billion acquisition of Talecris Biotherapeutics (NASDAQ:TLCR) now has the regulatory clearance to close. Barcelona, Spain-based Grifols said Wednesday that the U.S. Federal Trade Commission has accepted a consent agreement that outlines the conditions for merger of the blood therapeutics companies. Last month, the FTC and the companies reached a preliminary agreement that […]
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Talecris Biotherapeutics’ (NASDAQ:TLCR) $4 billion acquisition by Spanish company Grifols (MCE:GRF) looks like it will finally win regulatory approval. Barcelona-based Grifols said Monday that it has reached a preliminary agreement with the U.S. Federal Trade Commission that grants approval of the deal, but also calls for both blood therapeutics companies to sell certain assets. The […]
The Talecris Biotherapeutics acquisition by Spanish company Grifols (MCE:GRF) looks like it’s moving closer to receiving regulatory approval, at least that’s how stock traders view the deal. Bloomberg Businessweek reports that investors have grown more bullish on Talecris (NASDAQ:TLCR), particularly since the Research Triangle Park, North Carolina company extended the deadline to close the $3.4 […]
Talecris Biotherapeutics and Grifols are extending the closing date for their proposed $3.4 billion merger while Grifols continues to work with the U.S. Federal Trade Commission on clearing the deal.
North Carolina biotech company Talecris Biotherapeutics has received an orphan drug designation in Europe for a blood clot treatment under development. Talecris is developing Plasmin to treat acute peripheral arterial occlusion.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Talecris Biotherapeutics released fourth-quarter financial results that saw net income shoot up to $17.1 million due in part to stronger revenue for its blood therapeutics drugs.
Among the life science current events from last week: GSK layoffs, the impact of the Talecris-Grifols merger; Ohio State University's $100 million donation; Steris' FDA warning letter; and RedBrick Health's foray into healthcare social media.
Talecris Biotherapeutics shareholders will spend Valentine's Day voting whether to approve the $3.4 billion offer from Spanish company Grifols to buy the company. But the merger faces a more important test. The Federal Trade Commission could still block the deal on antitrust grounds as it did two years ago when CSL Limited tried to buy Research Triangle Park-based Talecris.